H.C. Wainwright Keeps Their Buy Rating on Asterias Biotherapeutics

By Ryan Adsit

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $12. The company’s shares closed last Friday at $3.15.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -8.6% and a 33.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and Synergy Pharmaceuticals Inc.

Asterias Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.67.

The company has a one year high of $5.80 and a one year low of $2.30. Currently, Asterias Biotherapeutics has an average volume of 171.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.